Efficacy of human-simulated aztreonam-avibactam against <i>Stenotrophomonas maltophilia</i> in the neutropenic murine thigh infection model
Aztreonam-avibactam HSR demonstrated in vivo efficacy against the majority of S. maltophilia isolates with MIC ≤4/4 mg/L in a neutropenic murine thigh infection model. These results provide decision support to standards development organizations for determination of susceptibility breakpoints for aztreonam-avibactam against S. maltophilia.
Authors
- Aliaa Fouad (ORCID: https://orcid.org/0009-0007-6467-1806)
- Yakun Fu (ORCID: https://orcid.org/0009-0008-9359-0930)
- Hanna F. Roenfanz (ORCID: https://orcid.org/0000-0002-0990-0932)
- Joseph L. Kuti (ORCID: https://orcid.org/0000-0002-4464-3126)
- David P. Nicolau (ORCID: https://orcid.org/0000-0002-4148-0165)
Institutions
- Hartford Hospital (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/jac/dkaf388
- Primary Topic
- Infections and bacterial resistance
- Type
- article
- Field-Weighted Citation Impact
- 0.00